HK Stock Market Move | CDAYENONFER (00661) surged over 15% in late trading, with a nearly 40% year-on-year increase in revenue for the first half of the year, and a significant turnaround from a loss to a profit.
Zhongya Yeyuan Metal (00661) surged over 15% at the close. As of the time of writing, it was up 15.07%, priced at HKD 0.168, with a transaction volume of HKD 13.2346 million.
CDAYENONFER (00661) surged over 15% in the late trading session. As of the time of writing, it is up 15.07%, priced at HKD 0.168, with a transaction volume of HKD 13.2346 million.
In terms of news, CDAYENONFER recently released its interim results, reporting a revenue of RMB 40.911 billion for the first half of the year, an increase of 39.6% year-on-year; net profit was RMB 442 million, compared to a loss of RMB 9.9 million in the same period last year, indicating a turnaround. The announcement stated that the increase in revenue was mainly due to rising prices of key products such as copper cathodes, gold, silver, and sulfuric acid. Additionally, in June this year, CDAYENONFER Mining announced that it plans to sell 100% of its design institute's equity for RMB 149 million to complete the divestment of non-core supporting assets.
Related Articles

How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.

RECOMMEND





